---
document_datetime: 2025-12-02 05:15:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cellcept.html
document_name: cellcept.html
version: success
processing_time: 0.1171614
conversion_datetime: 2025-12-29 22:08:11.93451
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# CellCept

[RSS](/en/individual-human-medicine.xml/66503)

##### Authorised

This medicine is authorised for use in the European Union

mycophenolate mofetil Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on CellCept](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

CellCept is a medicine used in adults and children from 1 year of age to prevent the body from rejecting a newly transplanted kidney, heart or liver. It is used together with ciclosporin and corticosteroids (other medicines to prevent the rejection of a transplanted organ).

CellCept contains the active substance mycophenolate mofetil.

Expand section

Collapse section

## How is CellCept used?

CellCept can only be obtained with a prescription. Treatment should be started and supervised by a doctor specialised in organ transplants.

CellCept is available as capsules, tablets or a powder to be made up into a liquid to be taken by mouth; in adults it can also be given by injection (drip) into a vein. How CellCept is given depends on the type of organ transplant. In children and adolescents, CellCept is only taken by mouth.

For more information about using CellCept, see the package leaflet or contact your doctor or pharmacist.

## How does CellCept work?

The active substance in CellCept, mycophenolate mofetil, is an immunosuppressant (a medicine that reduces the activity of the immune system). It is converted in the body into mycophenolic acid, which blocks an enzyme called inosine monophosphate dehydrogenase. This enzyme is important for the formation of DNA in cells, particularly in lymphocytes (a type of white blood cell involved in the rejection of organ transplants). By preventing the production of new DNA, CellCept reduces the rate at which the lymphocytes multiply. This makes them less effective at recognising and attacking the transplanted organ, lowering the risk of the organ being rejected.

## What benefit has CellCept shown during the studies?

Treatment with CellCept was shown to be effective at preventing the rejection of a newly transplanted kidney, heart or liver in adults and children from 1 year of age.

In all studies, CellCept was given with ciclosporin and corticosteroids, and the main measure of effectiveness was the proportion of patients whose new organ was rejected within six months of receiving the transplant. In most studies, CellCept was compared with azathioprine (another medicine to prevent transplant rejection) or placebo (a dummy treatment).

Kidney transplant

Three main studies involved a total of 1,493 adults who had received a kidney transplant. CellCept was as effective as azathioprine and more effective than placebo in preventing rejection of the new kidney in the first 6 months after transplantation.

A fourth study looked at the effects of CellCept in 100 children who had received a kidney transplant. This study did not compare CellCept with any other medicine or placebo. The proportion of children whose new kidney was rejected was similar to that seen in adults and lower than that seen in other studies of children who underwent a kidney transplant but did not receive CellCept.

Heart transplant

A main study involved 650 adults who had undergone a heart transplant. In the first 6 months after the transplant, the new heart was rejected in 37% of patients taking CellCept, compared with 38% of patients taking azathioprine.

Liver transplant

A main study involved 565 adults who had undergone a liver transplant. In the first 6 months after the transplant, the new liver was rejected in around 38% of patients taking CellCept, compared with around 48% of patients taking azathioprine. The proportion of patients whose new liver was lost after one year was similar in the two groups, at around 4%.

Use in children

The company provided data showing that CellCept behaves in the body in the same way across all age groups from 1 to 18 years of age. It is therefore expected to be effective in preventing rejection following a kidney, heart or liver transplant in these children. This is supported by data from the medical literature on the use of CellCept in children and adolescents.

## What are the risks associated with CellCept?

For the full list of side effects and restrictions with CellCept, see the package leaflet.

The most common side effects with CellCept combined with ciclosporin (which may affect more than 1 in 10 people) include diarrhoea, leucopenia, bacterial infections and vomiting.

Using CellCept during pregnancy can cause miscarriage and serious harm to a developing baby. Therefore, CellCept must not be used by women who are pregnant unless no other suitable treatment option is available to prevent rejection of the transplant. Women able to have children must take a pregnancy test before starting treatment to confirm that they are not pregnant. Both women and men should use an effective form of contraception before and during treatment with CellCept and for at least 6 weeks after. CellCept must not be used by women who are breastfeeding.

## Why is CellCept authorised in the EU?

Treatment with CellCept in combination with ciclosporin and corticosteroids is effective at preventing the rejection of a newly transplanted kidney, heart or liver in adults and children from 1 year of age.

The most serious risks with CellCept are the possible development of cancer (particularly lymphoma and skin cancer), infections (including serious infections), and serious harm to a developing baby. Considering the measures in place to minimise these risks and what the medicine is used for, the safety profile of CellCept is considered acceptable.

The European Medicines Agency therefore decided that CellCept's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of CellCept?

The company that markets CellCept will provide educational materials for patients and healthcare professionals, explaining the risk of serious harm to a developing baby, the precautions to be taken to avoid pregnancy during treatment and the course of action if a woman becomes pregnant during treatment. The materials will also inform patients not to donate blood during treatment or for at least 6 weeks after, and men not to donate semen during, or for at least 3 months after, treatment.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of CellCept have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of CellCept are continuously monitored. Suspected side effects reported with CellCept are carefully evaluated and any necessary action taken to protect patients.

## Other information about CellCept

CellCept received a marketing authorisation valid throughout the EU on 14 February 1996.

CellCept : EPAR - Medicine overview

Reference Number: EMA/552337/2024

English (EN) (112.23 KB - PDF)

**First published:** 12/03/2008

**Last updated:** 17/02/2025

[View](/en/documents/overview/cellcept-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-236)

български (BG) (139.77 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/bg/documents/overview/cellcept-epar-medicine-overview_bg.pdf)

español (ES) (114.56 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/es/documents/overview/cellcept-epar-medicine-overview_es.pdf)

čeština (CS) (137.72 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/cs/documents/overview/cellcept-epar-medicine-overview_cs.pdf)

dansk (DA) (114.73 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/da/documents/overview/cellcept-epar-medicine-overview_da.pdf)

Deutsch (DE) (118.56 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/de/documents/overview/cellcept-epar-medicine-overview_de.pdf)

eesti keel (ET) (112.69 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/et/documents/overview/cellcept-epar-medicine-overview_et.pdf)

ελληνικά (EL) (137.14 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/el/documents/overview/cellcept-epar-medicine-overview_el.pdf)

français (FR) (116.3 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/fr/documents/overview/cellcept-epar-medicine-overview_fr.pdf)

hrvatski (HR) (136.95 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/hr/documents/overview/cellcept-epar-medicine-overview_hr.pdf)

italiano (IT) (113.09 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/it/documents/overview/cellcept-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (144.53 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/lv/documents/overview/cellcept-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.71 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/lt/documents/overview/cellcept-epar-medicine-overview_lt.pdf)

magyar (HU) (138.65 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/hu/documents/overview/cellcept-epar-medicine-overview_hu.pdf)

Malti (MT) (142.91 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/mt/documents/overview/cellcept-epar-medicine-overview_mt.pdf)

Nederlands (NL) (115.16 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/nl/documents/overview/cellcept-epar-medicine-overview_nl.pdf)

polski (PL) (138.62 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/pl/documents/overview/cellcept-epar-medicine-overview_pl.pdf)

português (PT) (115.71 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/pt/documents/overview/cellcept-epar-medicine-overview_pt.pdf)

română (RO) (136.7 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/ro/documents/overview/cellcept-epar-medicine-overview_ro.pdf)

slovenčina (SK) (138.31 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/sk/documents/overview/cellcept-epar-medicine-overview_sk.pdf)

slovenščina (SL) (135.85 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/sl/documents/overview/cellcept-epar-medicine-overview_sl.pdf)

Suomi (FI) (112.39 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/fi/documents/overview/cellcept-epar-medicine-overview_fi.pdf)

svenska (SV) (113.73 KB - PDF)

**First published:**

12/03/2008

**Last updated:**

17/02/2025

[View](/sv/documents/overview/cellcept-epar-medicine-overview_sv.pdf)

CellCept : EPAR - Risk management plan

English (EN) (1.97 MB - PDF)

**First published:** 17/02/2025

[View](/en/documents/rmp/cellcept-epar-risk-management-plan_en.pdf)

## Product information

CellCept : EPAR - Product Information

English (EN) (1.25 MB - PDF)

**First published:** 27/10/2009

**Last updated:** 17/02/2025

[View](/en/documents/product-information/cellcept-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-377)

български (BG) (1.55 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/bg/documents/product-information/cellcept-epar-product-information_bg.pdf)

español (ES) (1.24 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/es/documents/product-information/cellcept-epar-product-information_es.pdf)

čeština (CS) (1.37 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/cs/documents/product-information/cellcept-epar-product-information_cs.pdf)

dansk (DA) (1.08 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/da/documents/product-information/cellcept-epar-product-information_da.pdf)

Deutsch (DE) (1.33 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/de/documents/product-information/cellcept-epar-product-information_de.pdf)

eesti keel (ET) (1.24 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/et/documents/product-information/cellcept-epar-product-information_et.pdf)

ελληνικά (EL) (1.77 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/el/documents/product-information/cellcept-epar-product-information_el.pdf)

français (FR) (1.32 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/fr/documents/product-information/cellcept-epar-product-information_fr.pdf)

hrvatski (HR) (1.4 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/hr/documents/product-information/cellcept-epar-product-information_hr.pdf)

íslenska (IS) (1.24 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/is/documents/product-information/cellcept-epar-product-information_is.pdf)

italiano (IT) (1.27 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/it/documents/product-information/cellcept-epar-product-information_it.pdf)

latviešu valoda (LV) (1.41 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/lv/documents/product-information/cellcept-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.48 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/lt/documents/product-information/cellcept-epar-product-information_lt.pdf)

magyar (HU) (1.45 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/hu/documents/product-information/cellcept-epar-product-information_hu.pdf)

Malti (MT) (1.74 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/mt/documents/product-information/cellcept-epar-product-information_mt.pdf)

Nederlands (NL) (1.25 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/nl/documents/product-information/cellcept-epar-product-information_nl.pdf)

norsk (NO) (1.25 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/no/documents/product-information/cellcept-epar-product-information_no.pdf)

polski (PL) (1.45 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/pl/documents/product-information/cellcept-epar-product-information_pl.pdf)

português (PT) (1.23 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/pt/documents/product-information/cellcept-epar-product-information_pt.pdf)

română (RO) (1.54 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/ro/documents/product-information/cellcept-epar-product-information_ro.pdf)

slovenčina (SK) (1.4 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/sk/documents/product-information/cellcept-epar-product-information_sk.pdf)

slovenščina (SL) (1.36 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/sl/documents/product-information/cellcept-epar-product-information_sl.pdf)

Suomi (FI) (1.26 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/fi/documents/product-information/cellcept-epar-product-information_fi.pdf)

svenska (SV) (1.18 MB - PDF)

**First published:**

27/10/2009

**Last updated:**

17/02/2025

[View](/sv/documents/product-information/cellcept-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0170/G 13/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

CellCept : EPAR - All Authorised presentations

English (EN) (20.69 KB - PDF)

**First published:** 06/04/2006

**Last updated:** 06/04/2020

[View](/en/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-455)

български (BG) (46.8 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/bg/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_bg.pdf)

español (ES) (20.57 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/es/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.05 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/cs/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.05 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/da/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.09 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/de/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.82 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/et/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (43.68 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/el/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_el.pdf)

français (FR) (19.03 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/fr/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (35.75 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/hr/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (17.45 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/is/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_is.pdf)

italiano (IT) (67.02 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/it/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (42.71 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/lv/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (39.87 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/lt/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.79 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/hu/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (39.58 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/mt/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (21.03 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/nl/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.74 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/no/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_no.pdf)

polski (PL) (40 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/pl/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.14 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/pt/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.8 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/ro/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (35.12 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/sk/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.64 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/sl/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.03 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/fi/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.8 KB - PDF)

**First published:**

06/04/2006

**Last updated:**

06/04/2020

[View](/sv/documents/all-authorised-presentations/cellcept-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine CellCept Active substance mycophenolate mofetil International non-proprietary name (INN) or common name mycophenolate mofetil Therapeutic area (MeSH) Graft Rejection Anatomical therapeutic chemical (ATC) code L04AA06

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (1 to 18 years of age) patients receiving allogeneic renal, cardiac or hepatic transplants.

## Authorisation details

EMA product number EMEA/H/C/000082 Marketing authorisation holder

Roche Registration GmbH

Emil-Barell-Strasse 1

Marketing authorisation issued 14/02/1996 Revision 40

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

CellCept : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (434.81 KB - PDF)

**First published:** 27/10/2009

**Last updated:** 17/02/2025

[View](/en/documents/procedural-steps-after/cellcept-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

CellCept-H-C-82-II-0170-G : EPAR - Assessment Report

Adopted

Reference Number: EMA/554250/2024

English (EN) (8.26 MB - PDF)

**First published:** 17/02/2025

[View](/en/documents/variation-report/cellcept-h-c-82-ii-0170-g-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for CellCept (II-170-G)

Adopted

Reference Number: EMA/178674/2024

English (EN) (130.37 KB - PDF)

**First published:** 15/11/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cellcept-ii-170-g_en.pdf)

CellCept-H-C-PSUSA-00010550-202305 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/148370/2024

English (EN) (97.54 KB - PDF)

**First published:** 11/04/2024

[View](/en/documents/scientific-conclusion/cellcept-h-c-psusa-00010550-202305-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

CellCept-H-C-PSUSA-00010550-202105 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/45415/2022

English (EN) (125.33 KB - PDF)

**First published:** 02/03/2022

[View](/en/documents/scientific-conclusion/cellcept-h-c-psusa-00010550-202105-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

CellCept-H-C-PSUSA-00010550-201705 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/187794/2018

English (EN) (68.66 KB - PDF)

**First published:** 26/03/2018

**Last updated:** 26/03/2018

[View](/en/documents/scientific-conclusion/cellcept-h-c-psusa-00010550-201705-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

CellCept-H-C-82-P46-0034 : EPAR - Assessment Report

Adopted

Reference Number: EMA/735864/2012

English (EN) (281.9 KB - PDF)

**First published:** 22/01/2013

**Last updated:** 22/01/2013

[View](/en/documents/variation-report/cellcept-h-c-82-p46-0034-epar-assessment-report_en.pdf)

CellCept : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (128.97 KB - PDF)

**First published:** 06/04/2006

**Last updated:** 06/04/2006

[View](/en/documents/steps-after-cutoff/cellcept-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

CellCept : EPAR - Scientific Discussion

English (EN) (439.78 KB - PDF)

**First published:** 06/04/2006

**Last updated:** 06/04/2006

[View](/en/documents/scientific-discussion/cellcept-epar-scientific-discussion_en.pdf)

CellCept : EPAR - Procedural steps taken before authorisation

English (EN) (85.09 KB - PDF)

**First published:** 06/04/2006

**Last updated:** 06/04/2006

[View](/en/documents/procedural-steps/cellcept-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on CellCept

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2024) 15/11/2024

[Mycophenolate: updated recommendations for contraception for men and women](/en/news/mycophenolate-updated-recommendations-contraception-men-women) 15/12/2017

[EMA recommends additional measures to prevent use of mycophenolate in pregnancy](/en/news/ema-recommends-additional-measures-prevent-use-mycophenolate-pregnancy) 23/10/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-october-2015) 23/10/2015

[European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection](/en/news/european-medicines-agency-finalises-review-medicines-concerned-roche-pharmacovigilance-inspection) 19/11/2013

[European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations](/en/news/european-medicines-agency-starts-infringement-procedure-investigate-roches-alleged-non-compliance-pharmacovigilance-obligations) 23/10/2012

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/02/2025

## Share this page

[Back to top](#main-content)